Roivant Sciences Stock Slips on Disappointing Earnings
16
3
BTCCSquare news:
Roivant Sciences (ROIV) opened the trading week with a 3% decline after reporting weaker-than-expected fiscal first-quarter results. Revenue plummeted to $2.2 billion from $8 billion year-over-year, while the company posted a GAAP net loss of $223 million against a year-ago profit. Analyst estimates of $7.7 billion in revenue and a $0.25 per-share loss were both missed.
The biotech firm's opaque financial disclosures—lacking detailed line items in its earnings release or SEC filing—likely exacerbated investor concerns. Roivant's unconventional structure, organizing operations into subsidiary "vants," further distinguishes it within the volatile biotech sector.
By:
